relaxin (mRNA-0184) / AstraZeneca, Moderna - LARVOL DELTA

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed | N=98 ➔ 48

Enrollment change • Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Feb 2025 ➔ Jul 2025 | Trial primary completion date: Feb 2025 ➔ Jul 2025

Trial completion date • Trial primary completion date

mRNA-CRTX-002: A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1 trial

Study to Investigate Safety and Tolerability of mRNA-0184 Administered at 2 Different Infusion Durations in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Jul 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date

Translational pharmacokinetic/pharmacodynamic model for mRNA-0184, an investigational therapeutic for the treatment of heart failure. (PubMed, Clin Transl Sci) - "The preclinical PK/PD model was then scaled allometrically to determine the human mRNA-0184 dose that would achieve therapeutic levels of Rel2-vlk protein expression in patients with stable HF with reduced ejection fraction. Model-based simulations derived from the scaled PK/PD model support the selection of 0.025 mg/kg as an appropriate starting human dose of mRNA-0184 to achieve average trough relaxin levels between 1 and 2.5 ng/mL, which is the potential exposure for cardioprotective action of relaxin."

Journal • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure (clinicaltrials.gov) - P1 | N=98 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

Study to Investigate Safety and Tolerability of mRNA-0184 Administered at 2 Different Infusion Durations in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Study to Investigate Safety and Tolerability of mRNA-0184 Administered at 2 Different Infusion Durations in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1 trial

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure (clinicaltrials.gov) - P1 | N=98 | Recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: May 2024 ➔ Mar 2025

Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure (clinicaltrials.gov) - P1 | N=98 | Recruiting | Sponsor: ModernaTX, Inc.

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure